INAB — IN8BIO, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1740279 ·
Last close
$1.03
Market Cap
$9.93M
52W High
$1.88
52W Low
$0.96
ADV30
50,433
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,266,000 | -5,090,000 | 26,265,000 | 21,941,000 | 3,484,000 |
| Dec 2025 | 0 | — | -5,033,000 | -4,942,000 | 32,282,000 | 27,092,000 | 4,724,000 |
| Sep 2025 | 0 | — | -3,967,000 | -3,854,000 | 16,768,000 | 10,689,000 | 3,579,000 |
| Jun 2025 | 0 | — | -5,201,000 | -5,094,000 | 19,371,000 | 13,226,000 | 4,132,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,712,000
Investing CF
$0
Financing CF
$28,638,000
CapEx
$-33,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.69
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-141,096,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-19,861,000
Pretax Income TTM
$-19,440,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -19,861,000 | -19,440,000 | 32,282,000 | 4,724,000 | — | -12,712,000 |
| Dec 2024 | 0 | -29,599,000 | -30,437,000 | 20,944,000 | 6,466,000 | — | -24,149,000 |
| Dec 2023 | 0 | -30,007,000 | -30,007,000 | 33,709,000 | 8,772,000 | — | -23,340,000 |
| Dec 2022 | 0 | -28,521,000 | -28,521,000 | 33,039,000 | 10,307,000 | — | -24,121,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | $9.93M | $0.90 | — |
| CUBT | Curative Biotechnology Inc | $9.90M | $1.29 | — |
| CRIS | CURIS INC | $9.78M | $5.02 | — |
| SNTI | Senti Biosciences Holdings, Inc. | $10.62M | $0.34 | — |
| ZEOX | Zeo ScientifiX, Inc. | $9.12M | $1.16 | — |
News headlines (Yahoo Finance, 1h cache)
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
2026-07-09 12:00 · Yahoo
IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
2026-06-04 13:55 · Yahoo
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
2026-06-03 12:30 · Yahoo
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
2026-06-01 12:30 · Yahoo
IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma
2026-05-14 12:00 · Yahoo
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-07 20:30 · Yahoo
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
2026-05-06 12:00 · Yahoo
RedChip's Biotech Virtual Investor Conference Replays Now Available
2026-04-21 19:00 · Yahoo
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
2026-04-07 15:00 · Yahoo
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-04-03 20:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.